IL254030D0 - שימוש בפרידופידין לשיפור תפקוד קוגניטיבי ולטיפול במחלת אלצהיימר - Google Patents

שימוש בפרידופידין לשיפור תפקוד קוגניטיבי ולטיפול במחלת אלצהיימר

Info

Publication number
IL254030D0
IL254030D0 IL254030A IL25403017A IL254030D0 IL 254030 D0 IL254030 D0 IL 254030D0 IL 254030 A IL254030 A IL 254030A IL 25403017 A IL25403017 A IL 25403017A IL 254030 D0 IL254030 D0 IL 254030D0
Authority
IL
Israel
Prior art keywords
בפרידופידין
קוגניטיבי
שימוש
אלצהיימר
במחלת
Prior art date
Application number
IL254030A
Other languages
Hebrew (he)
Inventor
Michael Hayden
Michal Geva
Ilya Bezprozvanny
Merav Bassan
Original Assignee
Michael Hayden
Teva Pharmaceuticals Int Gmbh
Univ Texas
Michal Geva
Ilya Bezprozvanny
Merav Bassan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201562120771P priority Critical
Priority to US201562186221P priority
Priority to PCT/US2016/019357 priority patent/WO2016138130A1/en
Application filed by Michael Hayden, Teva Pharmaceuticals Int Gmbh, Univ Texas, Michal Geva, Ilya Bezprozvanny, Merav Bassan filed Critical Michael Hayden
Publication of IL254030D0 publication Critical patent/IL254030D0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms
    • C07D211/24Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by sulfur atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
IL254030A 2015-02-25 2017-08-16 שימוש בפרידופידין לשיפור תפקוד קוגניטיבי ולטיפול במחלת אלצהיימר IL254030D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201562120771P true 2015-02-25 2015-02-25
US201562186221P true 2015-06-29 2015-06-29
PCT/US2016/019357 WO2016138130A1 (en) 2015-02-25 2016-02-24 Use of pridopidine to improve cognitive function and for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
IL254030D0 true IL254030D0 (en) 2017-10-31

Family

ID=56689699

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254030A IL254030D0 (en) 2015-02-25 2017-08-16 שימוש בפרידופידין לשיפור תפקוד קוגניטיבי ולטיפול במחלת אלצהיימר

Country Status (9)

Country Link
US (1) US20160243098A1 (en)
EP (2) EP3261721A4 (en)
JP (1) JP2018506569A (en)
AU (1) AU2016222796A1 (en)
CA (1) CA2977264A1 (en)
IL (1) IL254030D0 (en)
MX (1) MX2017010982A (en)
TW (1) TW201639570A (en)
WO (1) WO2016138130A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
PE20160195A1 (en) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Using pridopidina in high doses for the treatment of Huntington's disease
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
AR105434A1 (en) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Process for preparing pridopidina
WO2018053287A1 (en) * 2016-09-15 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of anxiety and depression
BR112019005040A2 (en) * 2016-09-16 2019-07-16 Prilenia Therapeutics Dev Ltd pridopidine application for rett syndrome treatment
CA3050700A1 (en) * 2017-01-20 2018-07-26 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (en) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission in
EP2508177A1 (en) * 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
EP2900226A4 (en) * 2012-09-27 2016-03-30 Teva Pharma Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
EP2900330A4 (en) * 2012-09-27 2016-05-25 Teva Pharma Laquinimod and pridopidine for treating neurodegenerative disorders
PE20160195A1 (en) * 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Using pridopidina in high doses for the treatment of Huntington's disease

Also Published As

Publication number Publication date
JP2018506569A (en) 2018-03-08
WO2016138130A1 (en) 2016-09-01
MX2017010982A (en) 2017-11-20
EP3261721A4 (en) 2018-08-08
EP3590512A1 (en) 2020-01-08
AU2016222796A1 (en) 2017-10-05
CA2977264A1 (en) 2016-09-01
EP3261721A1 (en) 2018-01-03
US20160243098A1 (en) 2016-08-25
TW201639570A (en) 2016-11-16

Similar Documents

Publication Publication Date Title
GB201419094D0 (en) Anti-TIM-3-antibodies
GB201404893D0 (en) Selfie - Stick
AU361515S (en) Dishrack
IL254030D0 (en) שימוש בפרידופידין לשיפור תפקוד קוגניטיבי ולטיפול במחלת אלצהיימר
GB201514938D0 (en) Braring calculation
PT3097397T (en) Schienenmesssystem
IL255194D0 (en) Solid forms
GB201707959D0 (en) No details
GB201612542D0 (en) no details
PL3122731T3 (en) Cyclohexylmethansulfonamides
AU201616677S (en) Cylindres
GB201706130D0 (en) No details
GB201509585D0 (en) -
GB2538731B (en) Methods
GB201415937D0 (en) Biofumigant
LT2990494T (en) Biobinder
GB201521751D0 (en) Novel uses
SG10201706761TA (en) Gyrostabilisers
GB201522311D0 (en) Use
GB201518762D0 (en) Methods
GB201501723D0 (en) Winics
GB201513390D0 (en) Aortopathy
SE1550032A1 (en) Gravitationsmotor
GB201506824D0 (en) TrailReach Multitrial
GB2545956B (en) Vibro-polishing arrangement